Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Study of GB-0998 in Patients With Unexplained Recurrent Miscarriage.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2022
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary)
- Indications Spontaneous abortion
- Focus Registrational; Therapeutic Use
- Sponsors Japan Blood Products Organization
- 05 Nov 2021 Status changed from recruiting to completed.
- 10 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2021.
- 10 Aug 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Jan 2021.